Alkermes plc (NasdaqGS:ALKS) in our automated value investing analysis, with the cash flow history and price comparison below.
Advertisement helps keep Trendshare free for most readers.
Estimate how long you need to hold Alkermes plc to reach your target.
Based on historical returns, we believe that Alkermes plc can grow its free cash at a rate of about 4%. That's positive!
| Advantages | Disadvantages | Neutral |
|---|---|---|
|
|
|
| ALKS Price (Alkermes plc stock price per share) |
$44.94 | |
|
|
ALKS Fair Price (based on intrinsic value) |
$10.83 |
| ALKS Safety Price (based on a variable margin of safety) | $7.04 | |
|
Try your own return
The fair price above uses a 10.1% discount rate, the long-run US stock return (10.1% geometric, 1926 to 2025, from Bessembinder's working paper, updated 2026-11-09), and 2.5% terminal growth. A higher rate suits a higher return target and gives a lower value. Value per share: |
||
| PE Ratio versus Sector | 506% higher than other Healthcare stocks | |
| PE Ratio versus Industry | 180% higher than other Drug Manufacturers - General stocks | |
| Cash Yield | 1.47% | |
| Free Cash Flow Jitter | 168% | |
No open-market insider buys or sells are recorded for the last 12 months.
This stock has short interest! This means that people have shorted it.
Why does that matter? They've made a bet that price will decrease from where they bought it. Maybe there are financial problems, or maybe there's a value play.
As of the latest analysis, there are 19,647,994 shares shorted. With 155,475,564 shares available for purchase and an average trading volume over the past 10 trading days of 1,480,470, it would take at least 13.3 days for all of the short holders to cover their shorts.
What does this mean to you? At this volume, it'll take more than two trading weeks for shorts to cover. This may indicate a short squeeze play would work! If this stock has good fundamentals and it'll take a while for the short holders to cover, buying now could net you bigger short-term technical gains if and as the price rises.
Related guides: good annual rate of return · high-yield stocks · forecasting earnings growth
How to read this: free cash flow in plain terms, free cash flow jitter.
Each year names the SEC filer that reported it, so a change of filer shows up here.
| Fiscal year | SEC filer (CIK) | Free cash flow (USD millions) |
|---|---|---|
| 2010 | 1520262 | -28 |
| 2011 | 1520262 | -18.5 |
| 2012 | 1520262 | -16.5 |
| 2013 | 1520262 | 131 |
| 2014 | 1520262 | -8.5 |
| 2015 | 1520262 | -67.4 |
| 2016 | 1520262 | -97.7 |
| 2017 | 1520262 | -21.6 |
| 2018 | 1520262 | 49.1 |
| 2019 | 1520262 | 10.4 |
| 2020 | 1520262 | 23.3 |
| 2021 | 1520262 | 45.3 |
| 2022 | 1520262 | -32.7 |
| 2023 | 1520262 | 352 |
| 2024 | 1520262 | 401 |
| 2025 | 1520262 | 483 |
Download the yearly data as CSV.
How to read this: what free cash flow is, why earnings matter.
Over the 4 fiscal years from 2010 to 2025 with positive net income, operating cash flow totaled $1,509 million against net income of $989 million, or 1.52 times. Net income was negative in 12 of the 16 years, and those years are left out of the ratio.
In 2025, capital expenditures were $40.4 million, 7.8% of operating cash flow of $521 million, which leaves an estimated $480 million after capex. Across the 11 years with reported capex, it averaged 26.0% of operating cash flow. This uses that year's own capital expenditures, not the five-year average behind the free cash flow table, so the two can differ.
| Fiscal year | Net income (USD millions) | Operating cash flow (USD millions) | Capital expenditures (USD millions) | Operating cash flow / net income |
|---|---|---|---|---|
| 2010 | -39.6 | -12.2 | 15.8 | n/a |
| 2011 | -45.5 | -5.9 | 9.4 | n/a |
| 2012 | -114 | -2.5 | 17 | n/a |
| 2013 | 25 | 148 | 22.2 | 5.91 |
| 2014 | -30.1 | 11.1 | 33.7 | n/a |
| 2015 | -227 | -40.4 | 52.9 | n/a |
| 2016 | -208 | -63.8 | 43.7 | n/a |
| 2017 | -158 | 19.2 | 51.3 | n/a |
| 2018 | -139 | 99.3 | 69.4 | n/a |
| 2019 | -197 | 72.1 | 90.9 | n/a |
| 2020 | -111 | 82.8 | 42.2 | n/a |
| 2021 | -48.2 | 102 | 28 | n/a |
| 2022 | -158 | 21 | 38.3 | n/a |
| 2023 | 356 | 401 | 48 | 1.13 |
| 2024 | 367 | 439 | 33.5 | 1.20 |
| 2025 | 242 | 521 | 40.4 | 2.15 |
How to read this: earnings and margins.
Revenue was $178 million in 2010 and $1,476 million in 2025, a compound annual growth rate of 15.1% over 15 years.
Revenue fell 5.2% from 2024 to 2025.
Our estimated free cash flow was $483 million in 2025, 32.7% of revenue. In 2010 the estimated margin was negative 15.7%. This estimate charges each year with the average of up to five years of capital expenditures, so it is not the free cash flow the company reported.
| Fiscal year | Revenue (USD millions) | Estimated free cash flow (USD millions) | Estimated free cash flow / revenue |
|---|---|---|---|
| 2010 | 178 | -28 | -15.7% |
| 2011 | 187 | -18.5 | -9.9% |
| 2012 | 390 | -16.5 | -4.2% |
| 2013 | 596 | 131 | 22.0% |
| 2014 | 619 | -8.5 | -1.4% |
| 2015 | 628 | -67.4 | -10.7% |
| 2016 | 746 | -97.7 | -13.1% |
| 2017 | 903 | -21.6 | -2.4% |
| 2018 | 1,094 | 49.1 | 4.5% |
| 2019 | 1,171 | 10.4 | 0.9% |
| 2020 | 1,039 | 23.3 | 2.2% |
| 2021 | 1,174 | 45.3 | 3.9% |
| 2022 | 1,112 | -32.7 | -2.9% |
| 2023 | 1,663 | 352 | 21.2% |
| 2024 | 1,558 | 401 | 25.8% |
| 2025 | 1,476 | 483 | 32.7% |
How to read this: how debt and assets are compared, the current ratio.
In 2025, cash and equivalents were $389 million against total liabilities of $668 million, or 58.2% of total liabilities. Total liabilities include everything the company owes, not only borrowed money.
Total liabilities were 26.8% of total assets in 2025, compared with 13.4% in 2011, an increase of 13.5 percentage points.
Stockholders equity was $1,819 million in 2025, compared with $392 million in 2011, a rise of 364.1%.
Based on our estimated free cash flow, cash flow return on invested capital (CROIC) was 31.1% in 2025. Invested capital here is total assets less cash and current liabilities.
| Fiscal year | Total assets (USD millions) | Cash and equivalents (USD millions) | Total liabilities (USD millions) | Stockholders equity (USD millions) |
|---|---|---|---|---|
| 2011 | 452 | 38.4 | 60.4 | 392 |
| 2012 | 1,435 | 83.6 | 581 | 854 |
| 2013 | 1,578 | 168 | 512 | 1,065 |
| 2014 | 1,919 | 224 | 522 | 1,397 |
| 2015 | 1,856 | 181 | 541 | 1,314 |
| 2016 | 1,726 | 186 | 517 | 1,209 |
| 2017 | 1,797 | 191 | 594 | 1,203 |
| 2018 | 1,825 | 267 | 654 | 1,171 |
| 2019 | 1,805 | 204 | 720 | 1,085 |
| 2020 | 1,950 | 273 | 883 | 1,067 |
| 2021 | 2,024 | 338 | 912 | 1,113 |
| 2022 | 1,964 | 292 | 920 | 1,044 |
| 2023 | 2,136 | 457 | 934 | 1,203 |
| 2024 | 2,056 | 291 | 591 | 1,465 |
| 2025 | 2,487 | 389 | 668 | 1,819 |
Free cash flow was positive in 8 out of 16 reported years for Alkermes plc, using only its current SEC filer.
Free cash flow is volatile from year to year, with a variability measure of 168%.
At $44.94, the price is above our fair value estimate of $10.83 for Alkermes plc.
Dividends are not in our data for Alkermes plc.
Our value investing guide explains how to test these numbers against the filings themselves.
How to read this: the price to earnings ratio.
Its trailing P/E ratio is 506% above the average for stocks in the Healthcare sector.
Its trailing P/E ratio is 180% above the average for stocks in the Drug Manufacturers - General industry.
A P/E ratio depends on trailing earnings, which one-time items can distort, so a lower P/E is not by itself evidence of value.
These are companies in the Drug Manufacturers - General industry, the ones closest in market capitalization to Alkermes plc, limited to companies whose pages we publish. The figures come from our latest data for each company.
| Company | Market cap (USD millions) | P/E | Dividend yield | Cash yield | Price versus our estimate |
|---|---|---|---|---|---|
| Alkermes plc (ALKS) | 7,552 | - | - | 1.5% | 315% above |
| Corcept Therapeutics Incorporated (CORT) | 7,112 | 48.9 | - | 0.0% | 858% above |
| Prestige Consumer Healthcare (PBH) | 2,352 | 15.3 | - | 7.8% | 50% below |
| Elanco Animal Health Incorporated (ELAN) | 12,866 | - | - | - | 96% above |
| Perrigo Company plc (PRGO) | 2,213 | - | 7.2% | 72.9% | 91% below |
| ANI Pharmaceuticals (ANIP) | 1,558 | 13.9 | - | - | 188% above |
| Phibro Animal Health Corporation (PAHC) | 1,352 | 13.9 | 1.4% | - | 82% above |
Industry labels are approximate, and companies in one industry can run quite different businesses, so a peer may not be a close match.
Ratios on different fiscal calendars are not strictly comparable, and a trailing P/E can be distorted by one-time items.
Every fiscal year on this page is reported by one SEC filer, CIK 1520262.
Each figure on this page comes from that filer.
How to read this: understanding investment risk.
Company figures come from the annual reports (Form 10-K) that each company files with the SEC, read from the SEC EDGAR company facts data. The share price and other market data come from a market data provider.
Free cash flow here is operating cash flow minus capital spending. To keep one unusual year from swinging the result, each year is charged with the average of up to five years of capital spending, so the figure is an estimate and not the free cash flow a company reports.
The fair price is the present value of ten years of projected free cash flow plus a terminal value, discounted at 10.1 percent a year, the long-run return of US stocks, with 2.5 percent growth after year ten. The figures on this page are estimates, not advice.
This analysis covers US companies that file 10-K annual reports. Free cash flow describes banks, real estate investment trusts and funds poorly, so treat their figures with extra caution. In the cash returned and balance sheet tables, a value of zero is treated as a gap in the data, not as a real zero.
Read the filings yourself: ALKS annual reports (10-K) on SEC EDGAR. To try your own growth rate, use the intrinsic value calculator on this page. Our editorial standards explain how Trendshare handles its sources and corrections.
Advertisement supports free stock analysis content.
Does Alkermes plc have a coherent story? Does it have a plan to continue to make money? Is it worth your time? Only you can decide where to go from here. Our investment guide helps you ask the right questions, including how to buy stocks. Use these research links for more information.
This example shows how we apply the Trendshare checklist to ALKS: earnings power, cash generation, valuation, and margin of safety.
We check: business quality, free cash flow, P/E, and margin of safety.
Most Popular Articles
What is the Difference Between Trading Stocks and Investing?
Why Do Companies Perform Stock Buybacks?
How Does Portfolio Churning Affect Your Returns?
How Do Tariffs Affect the Stock Market?
DCA vs Lump Sum: 155 Years of S&P 500 Historical Data
How to Invest $1000 in the Stock Market